Monte Rosa Therapeutics (GLUE) Shares Outstanding (Weighted Average) (2020 - 2026)

Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) history runs 7 years deep, the most recent figure standing at $99.9 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 21.59% year-over-year to $99.9 million; the TTM figure through Mar 2026 stood at $99.9 million (up 21.59% YoY), while the FY2025 annual figure was $83.1 million, up 12.4% from the prior year.
• Shares Outstanding (Weighted Average) was $99.9 million for Q1 2026 at Monte Rosa Therapeutics, up from $83.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $99.9 million in Q1 2026 to a low of $46.6 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $64.6 million across 5 years, with a median of $60.2 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Weighted Average) soared 2626.13% in 2022, then increased 0.28% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $47.2 million in 2022, then gained by 8.83% to $51.4 million in 2023, then surged by 43.8% to $73.9 million in 2024, then rose by 12.4% to $83.1 million in 2025, then advanced by 20.24% to $99.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $99.9 million (Q1 2026), $83.1 million (Q4 2025), and $82.2 million (Q3 2025), per Business Quant data.